GlassScriptPhysician profile
Brian S Wojciechowski
NPI 1730340639
$11,894.15
in general payments reported to CMS, 2019-2025
68 companies · $3,694 in 2025
The $3,694 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,440 · 2020: $2,142 · 2021: $531 · 2023: $110 · 2024: $2,977 · 2025: $3,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,538 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,537.54 |
| Education | $243.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $1,055.76 | 2019-2024 | Tavalisse, Rezlidhia |
| Novartis Pharmaceuticals Corporation | $753.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $749.54 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $737.02 | 2019-2025 | Erleada, Tecvayli, Talvey |
| Pfizer INC. | $712.74 | 2019-2025 | |
| Daiichi Sankyo INC. | $559.18 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $527.98 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $503.57 | 2019-2025 | Opdualag, Opdivo, Eliquis |
| Incyte Corporation | $431.87 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Genentech USA, INC. | $414.15 | 2019-2025 | Venclexta, Polivy, Tecentriq Hybreza |
| Celgene Corporation | $373.14 | 2019-2025 | Reblozyl |
| Astellas Pharma US INC | $341.65 | 2019-2025 | Vyloy, Xtandi, Xospata |
| Abbvie INC. | $315.21 | 2020-2025 | |
| Lilly USA, LLC | $286.14 | 2019-2025 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $274.41 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wojciechowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.